Size dependent PASylation critically regulates H-Ferritin nanocage stability and functionality

Beatrice Bignami,[1] Francesca Gorgoglione,[1,†] Valeria Giacobbo,[1] Marta Sevieri,[1] Claudia Pigliacelli,[2] Francesca Baldelli Bombelli,[2] Renata Tisi,[4] Fabio Corsi,[1,3] Serena Mazzucchelli[1]

1. Nanomedicine Laboratory, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy; 2. Dipartimento di Chimica, Materiali, ed ingegneria chimica "Giulio Natta", Politecnico di Milano, Milano, 20131, Italy; 3. Istituti Clinici Scientifici Maugeri IRCCS, via Maugeri 4, 27100 Pavia, Italy;4. Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, 20126 Milano, Italy.

Scan me!

Introduction

Over the past two decades, cancer nanomedicine has focused on nanosystems able to **specifically deliver anticancer drugs to tumors**, improving efficacy while reducing side effects. Among these, **Herritin nanocages (HFn)** stand out due to their **biocompatibility, low immunogenicity, and natural tumor homing** via the transferrin receptor (TfR1), commonly overexpressed in cancers [1].

HFn are characterized by a **hollow cavity** (8 nm) and can **efficiently encapsulate drugs and imaging agents** (e.g., doxorubicin and indocyanine green), showing strong results in vitro and in animal models [2-7].



However, their clinical performance is limited by **short circulation time and rapid clearance**, leading to **suboptimal tumor accumulation.**

To overcome these limitations, surface engineering strategies have been explored [8]. Among them, **PASylation**, which is the addition of a flexible sequence of proline (P), alanine (A), and serine (S), **resulted in improved stability, circulation time, and bioavailability while preserving tumor targeting** [9]. PAS domains ≥ 40 amino acids have been explored, displaying improved in vivo performance [10].

At present, the effects of shorter PAS sequences remain unknown.

Aim

Investigate how shorter PAS chains influence HFn-nanocage stability and functionality.

Nanocages design



PAS sequences of different lengths (40 and 20 amino acids) were inserted in N-term. position followed by a sequence cleavable by Tumor metalloproteases (MMP).

Different behavior of PAS20 and PAS40-HFn

PAS20-HFn: quaternary structure instability and no nanocages in charge–rich environment



PAS40-HFn: Stable and monodisperse nanocage

PAS20-HFn characterization



Absence of PAS20-HFn nanocages when purified with IEC (A), while SEC allows PAS20-HFn nanocages purification (B). The charged resin (MonoQ Sepharose) used for IEC purification disrupts nanocages (C).

Molecular dynamics







Molecular dynamics revealed high flexibility of PAS20-HFn, which displaces the **158–168 regions** located on adjacent dimers in the tetramer, involved in stabilizing quaternary structure interactions.

PAS20-HFn functional alterations

ICG loading: pH-dependent method

	PAS40-HFn@ICG	PAS20-HFn@ICG	HFn@ICG
ICG encapsulated (mg)	1.50 ± 0.67	0.22 ± 0.06	1.29 ± 0.31
% recovery	26.66 ± 7.52	1.08 ± 0.31	31.07 ± 7.87



Cleavage assay

Complete PAS domain removal observed in nanocages after 120h; no cleavage in monomers fraction.

Binding assay

Following PAS domain removal, binding to the TfR1 receptor is restored in both mutants.



Conclusions

- ✓PASylation exert a bipolar and size-dependent effect of HFn nanocages
- ✓While longer PAS domain enhance stability and functionality, excessively short PAS sequences destabilize oligomerization and compromise drug loading
- ✓PAS length is a critical design parameter for engineering effective HFn- based nanomedicines

[1] Giacobbo V. et al. Exp. Op. on Drug Delivery, 2026; doi.org/10.1080/17425247.2025.2584632
[2] Sevieri, M., et al. ACS Omega, 2023, DOI: 10.1021/acsomega.3c05566
[3] Mazzucchelli, S., et al. Oncotarget, 2017, DOI: 10.18632/oncotarget.14204
[4] Bonizzi, A., et al. Pharmaceutics, 2019 DOI: 10.3390/pharmaceutics11080384
[5] Sevieri, M., et al. Int. J. Molecular Sciences, 2021, DOI: 10.3390/IJMS22041601
[6] Andreata, F., et al. Sci. Reports, 2020, DOI: 10.1038/s41598-020-68205-w.
[7] Sevieri, M., et al. Journal of Nanobiotechnology, 2024, 22(1), DOI: 10.1186/s12951-024-02441-4
[8] Sevieri, M., et al. ACS Omega, 2023, 8(8):7244–7251, DOI: https://doi.org/10.1021/acsomega.2c07794
[9] Schlapschy, M., et al. Protein Engineering, Design and Selection, 2013, DOI: 10.1093/protein/gzt023
[10] Falvo, Eet al. Biomacromolecules, 2016, DOI: 10.1021/acs.biomac.5b01446

For re-use permission contact serena.mazzucchelli@unimi.it

Funding:
AIRC IG-ID27107 PI Mazzucchelli S.